UNSPSC 51385300: Nonsteroidal anti inflammatory quinazolinones

UNSPSC 51385300 Nonsteroidal anti inflammatory quinazolinones is a Class code with limited recent activity directly aligned to its nominal scope. The recent opportunities posted under this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products supplied through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which are nonsteroidal anti-inflammatory quinazolinones. The actual buying activity reflects broader pharmaceutical procurement including emergency response medications, generic drug supply chains, and pharmacy benefit program restructuring, suggesting that state and local issuing bodies are using this code for general pharmaceutical and pharmaceutical-adjacent purchasing rather than for the specific drug class the code name describes. Issuing bodies include counties (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance).

Recent opportunities span Florida, Texas, and Minnesota-led multi-state cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative vehicle, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The code shows sparse and scattered activity with limited geographic concentration; pursuit under this code requires verification that the specific pharmaceutical category aligns with actual agency requirements rather than reliance on the code's nominal definition.